Genmab — Regulatory Filings 2013

Feb 28, 2013

News Details

Ad-hoc | 28 February 2013 19:39

Genmab Announces Sale of Manufacturing Facility to Baxter

Genmab A/S

28.02.2013 19:39

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

**Company Announcement

- Genmab sells manufacturing
facility to Baxter Healthcare Corporation
- Genmab receives USD 10
million

Copenhagen, Denmark; February 28,
2013 - Genmab A/S (OMX: GEN) announced today the signing and
closing of an agreement with Baxter Healthcare Corporation for the sale of
Genmab's non-plasma-derived antibody manufacturing facility, located in
Brooklyn Park, Minnesota, USA, for USD 10 million. Under the terms of the agreement Genmab receives the
USD 10 million (approximately DKK 57 million) in cash and Baxter acquires the
facility, land, and equipment at the Brooklyn Park site. Baxter will offer
employment to the 23 employees currently supporting the facility.

'We have
delivered on our commitment to execute the sale of the antibody manufacturing
facility in the first quarter of this year and are very pleased that Baxter
acquired the facility, including the 23 employees who have maintained the
facility to such a high standard,' said Jan van de Winkel, Ph.D., Chief
Executive Officer of Genmab.

**About Genmab A/S
Genmab is a publicly traded, international
biotechnology company specializing in the creation and development of
differentiated human antibody therapeutics for the treatment of cancer.
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)),
was approved to treat chronic lymphocytic leukemia in patients who are
refractory to fludarabine and alemtuzumab after less than eight years in
development. Genmab's validated and next generation antibody technologies are
expected to provide a steady stream of future product candidates. Partnering
of innovative product candidates and technologies is a key focus of Genmab's
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com.

**Contact:
Rachel
Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E:
r.gravesen@genmab.com

*This Company Announcement contains
forward looking statements. The words 'believe', 'expect', 'anticipate',
'intend' and 'plan' and similar expressions identify forward looking
statements. Actual results or performance may differ materially from any future
results or performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the risk
management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by
law.

Genmab A/S and its subsidiaries own the following
trademarks: Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); DuoBody(r), HexaBody(TM) and UniBody(r). Arzerra(r) is a trademark of
GlaxoSmithKline.

Company Announcement no. 04
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=421169

News Source: NASDAQ OMX

28.02.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Dänemark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------***